AIM: To investigate the curative effect and safety of glass body cavity injection of Conbercept glass valve body cavity injection combined with Ahmed valve implantation and whole retinal photocoagulation in treatment of neovascular glaucoma with visual function.

METHODS: Retrospective analysis of our hospital from 2015 Jan. to 2015 Dec., 12 cases of neovascular glaucoma patients with visual function were treated with glass body cavity injection of Conbercept 0.5mg, after waiting for iris neovascular fade, glaucoma valve implantation and retinal photocoagulation. All the cases were follow-up for 3mo. Visual acuity, intraocular pressure, complications and so on were observed and recorded.

RESULTS: After 3mo follow-up, vision improvement 10 eyes, constant vision 1 eye and decreased vision 1 eyes average intraocular pressure decreased significantly(41.22±8.29 mmHg vs 16.08±4.92 mmHg, P<0.05). No serious complications were observed, only one eye was found shallow of anterior chamber, and recovered in 1wk. A small amount of blood in the anterior chamber was observed in 1 eye, and absorbed 3d later. Vitreous body hematocele was diagnosed in 1 eye treated with whole retinal photocoagulation after 1mo later. After vitreous body cutting applied, vision was partly recovered and intraocular pressure was stable.

CONCLUSION: Conbercept glass valve body cavity injection combined with Ahmed valve implantation and whole retinal photocoagulation treatment is a safe and effective method for neovascular glaucoma with visual function.